by zhaoq | Sep 29, 2025 | News Article
Former House Speaker Newt Gingrich recently cited our center’s study in his article on U.S. drug pricing, noting that the research “flips the narrative on its head.” The study compares drug prices in the United States, Canada, Germany, the United Kingdom, France, and...
by deyuz | Sep 29, 2025 | News Article
By Prof. Em. Tomas J. Philipson Not vice versa. Conventional wisdom holds that prices for prescription drugs paid by our government are substantially higher in the United States than abroad. This has led to various forms of price controls on drugs in the U.S., first...
by sfrazee | Aug 14, 2024 | News Article, Uncategorized
By Prof. Casey B. Mulligan and Em. Prof. Tomas J. Philipson Democrats don’t understand healthcare markets. We agree with your editorial “Biden Does a Stealth Medicare Rewrite” (Aug. 6) on the Inflation Reduction Act’s harm to the Medicare drug program. Two years ago,...
by mheinl | Sep 27, 2023 | News Article
by Tomas J. Philipson in The National Review Capital Matters “The Inflation Reduction Act’s Medicare price controls create bad incentives for drug development and access. This month, the Biden administration announced the initial ten drugs, of an eventual...
